Isotechnika Cleared by FDA to Commence Phase 3 Voclosporin Trial

 
Isotechnika Cleared by FDA to Commence Phase 3 Voclosporin Trial
 

 

EDMONTON, Alberta, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Isotechnika Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that it has received permission from the U.S. Food and Drug Administration ("FDA") to commence the first of two planned phase 3 kidney transplant trials for its lead product candidate, voclosporin